About Tissue alpha-L-fucosidase
Tissue alpha-L-fucosidase (FUCA1) is a protein
from Homo sapiens identified by UniProt accession
P04066, 466 residues long.
MolForge cross-references it against 0 known binders and
192 disease associations.
Target properties
| Protein name | Tissue alpha-L-fucosidase |
| UniProt accession | P04066 |
| Gene | FUCA1 |
| Organism | Homo sapiens |
| Length | 466 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (192)
Diseases linked to this target (Open Targets).
- fucosidosis · score 0.84
- genetic disorder · score 0.41
- Intellectual disability · score 0.37
- Seizure · score 0.37
- Abnormality of the nervous system · score 0.34
- lymphocyte count · score 0.26
- reticulocyte count · score 0.26
- reticulocyte measurement · score 0.23
- eosinophil count · score 0.21
- Immature Reticulocyte Fraction Measurement · score 0.21
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P04066-F1 | alphafold | PREDICTED | 93.19 | — |
Amino-acid sequence (466 residues)
MRAPGMRSRP AGPALLLLLL FLGAAESVRR AQPPRRYTPD WPSLDSRPLP AWFDEAKFGV FIHWGVFSVP AWGSEWFWWH WQGEGRPQYQ RFMRDNYPPG FSYADFGPQF TARFFHPEEW ADLFQAAGAK YVVLTTKHHE GFTNWPSPVS WNWNSKDVGP HRDLVGELGT ALRKRNIRYG LYHSLLEWFH PLYLLDKKNG FKTQHFVSAK TMPELYDLVN SYKPDLIWSD GEWECPDTYW NSTNFLSWLY NDSPVKDEVV VNDRWGQNCS CHHGGYYNCE DKFKPQSLPD HKWEMCTSID KFSWGYRRDM ALSDVTEESE IISELVQTVS LGGNYLLNIG PTKDGLIVPI FQERLLAVGK WLSINGEAIY ASKPWRVQWE KNTTSVWYTS KGSAVYAIFL HWPENGVLNL ESPITTSTTK ITMLGIQGDL KWSTDPDKGL FISLPQLPPS AVPAEFAWTI KLTGVK
Explore Tissue alpha-L-fucosidase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets